Pulse Biosciences, Inc. (NASDAQ: PLSE) disclosed insider transactions by its Chief Commercial Officer, Kevin Patrick Danahy, who sold 60,000 shares of common stock over the span of February 12 to February 17, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the sales totaled $1.41 million and were completed at weighted average prices ranging from $23.37 to $23.63 per share.
The filing also shows that Danahy exercised options to acquire 60,000 shares of Pulse Biosciences common stock at an exercise price of $1.53. That exercise produced a total value of $91,800. The sales were conducted under a pre-established Rule 10b5-1 trading plan that Danahy adopted on May 14, 2025. Following the option exercise and the subsequent share sales, Danahy's direct ownership in the company stands at 43,298 shares.
Alongside the disclosure of insider activity, Pulse Biosciences provided updates on several clinical and regulatory fronts. The company reported promising results from a feasibility study of its nPulse Cardiac Catheter System used to treat atrial fibrillation. In that study - which covered 150 patients - the procedure demonstrated a 100% procedural success rate at six months and a 96% success rate at twelve months. The study findings, as released by the company, also highlighted rapid procedure times and minimal observed adverse effects across the patient group.
Regulatory progress is a notable component of Pulse's recent announcements. The U.S. Food and Drug Administration has approved an Investigational Device Exemption (IDE) for the company, enabling the start of the NANOPULSE-AF clinical study. That study is designed to evaluate the safety and effectiveness of Pulse Biosciences' technology in the treatment of paroxysmal atrial fibrillation.
Beyond cardiac applications, Pulse Biosciences plans to initiate a clinical trial in 2026 in collaboration with The University of Texas MD Anderson Cancer Center. That study will investigate the nPulse Vybrance Percutaneous Electrode System for the treatment of thyroid cancers, specifically assessing the safety and effectiveness of nanosecond Pulsed Field Ablation technology for papillary thyroid microcarcinoma.
Market attention to the company's prospects was underscored by the start of analyst coverage from Mizuho, which initiated coverage on Pulse Biosciences with an Outperform rating and a $25 price target. Mizuho's assessment, as stated in the company's announcement, referenced positive physician feedback and what it described as rapid adoption of the technology following FDA clearance.
The filings and clinical updates released by Pulse Biosciences outline both an active executive stock transaction and a set of advancing development programs. The insider sale and option exercise are presented as executed under an existing trading plan, while the clinical data, regulatory clearance for an IDE, and forthcoming studies represent ongoing steps in the company’s development pipeline.